Table 2 Clinical characteristics of the patients (n = 56).
From: FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy
Characteristics | Median[range], n(%) |
|---|---|
Clinical characteristics | |
Demographic parameters | |
Age (years) | 68 [40–84] |
Female | 27 (48%) |
Male | 29 (52%) |
PET Centre | |
Saint-Etienne PET Centre | 33 (59%) |
Siemens, Biograph 6 HI-REZ | 14 (25%) |
Siemens, Biograph 20 mCT | 19 (34%) |
Grenoble PET Centre | 23 (41%) |
GE, Discovery 690 | 12 (21%) |
Siemens, Biograph Horizon 16 | 11 (20%) |
Metastatic status (8th AJCC classification) | |
M1a | 13 (23%) |
M1b | 5 (9%) |
M1c | 31 (55%) |
M1d | 7 (13%) |
Treatment | |
Median duration between PET and start of treatment (months) | 1.1 [0.03–9.07] |
Follow-up | |
Duration (months) | 22.1 [2.1–49.2] |
Survival | |
Death | 21 (38%) |
